Your browser is out of date

With an updated browser, you will have a better Medtronic website experience. Update my browser now.

×

Skip to main content
This will play a video. - Loving mother and daughter having a cup of coffee at home and spending quality time together

Medtronic DBS DBS therapy for Parkinson's disease

Deep brain stimulation (DBS) helps control the movement symptoms of Parkinson’s disease, including tremor, slowed movement and stiffness.
This will play a video. - BrainSense Adaptive loop banner

Introducing BrainSense™ Adaptive deep brain stimulation (aDBS)

If you are interested in DBS surgery or if you already have a Percept™ device, ask your doctor about BrainSense™ aDBS
Learn more

DBS Therapy

Every day, we want to feel life in all its colors and shades. But little by little, Parkinson’s chips away those moments, those minutes and so many of life’s simple pleasures.

You are not alone. Medtronic DBS therapy can help you improve your quality of life and feel more like your old self again.

I still feel better now after 10 years of DBS than before my surgery.

BE MORE CONFIDENT, LIKE LAURA

85–89% OF PEOPLE

with Parkinson’s who have DBS surgery experience improvements, if candidates are carefully selected and if the lead is correctly placed.2

EXPLORE THE BENEFITS

For the first time in years I was walking properly.

BE MORE AT EASE, LIKE NICK

References

1

Based on recommendations by European and national medical societies

Analyses based on PD comorbidities recommended for MRI in Europe. The % was calculated for a real-life PD population potentially eligible for DBS, from US commercial health insurance database (Conroy et al, conference presentation, ECR 2015, Vienna).

2

Medtronic supplemental analysis: supplement to EPDA website update re patient barriers and claims-v17-Sept-2015

The 'gold standard' of evaluating the success rate of DBS is based on the overall motor function evaluation using the UPDRS III scale. The scientifically accepted method for evaluation of the MCIC (minimally clinically important change) is at least 5 points in the UPDRS III scale. The evaluation of 'off medication' allows reflection of the impact of DBS, albeit an artificially created 'off' condition. It has not been typically reported in the publications, but we have completed the above additional analyses of the databases available in both the published evidence (only randomised control trials have been considered for this). The above analysis works for Medtronic devices only.

Disclaimer

Information contained herein is not medical advice and should not be used as an alternative to speaking with your doctor.

Discuss indications, contraindications, warnings, precautions, adverse events and any further information with your health care professional. Please note that the intended use of a product may vary depending on geographical approvals.

Medtronic products placed on European markets bear the CE mark and the UKCA mark (if applicable).